(ACTION) Adoptive Cellular Therapy following Dose-Intensified Temozolomide in Newly-diagnosed Pediatric High-grade Gliomas
It is believed that the body's immune system protects the body by attacking and killing tumor cells. T-lymphocytes (T-cells) are part of the immune system and can attack when they recognize special proteins on the surface of tumors. In most patients with advanced cancer, T-cells are not stimulated enough to kill the tumor.
In this research study, we will use a patient's tumor to make a vaccine which we hope will stimulate T-cells to kill tumor cells and leave normal cells alone.
- 3 - 21 years old
- Patients with histologically confirmed WHO Grade III or IV malignant glioma
- Scheduled for definitive surgical resection of suspected HGG (biopsy only subjects are not eligible for this study)
Can be done from home
KeywordsBrain Tumors, Pediatric Brain Tumors, Brain Tumor, Brain tumor - children, Glioma
Principal InvestigatorElias Sayour, MD, PhD
Begin a new search for other research studies
Studies listed on this site have been approved by a UF Institutional Review Board (IRB), which works to ensure the welfare and rights of research participants as required by federal regulations. Study listings are provided by the UF Clinical and Translational Science Institute in collaboration with UF research teams and the UF IRBs.